This trial is looking at whether T cells can help people with adenovirus, CMV, or EBV infections who have received transplants or have weakened immunity.
- Epstein-Barr Virus (EBV) Infection
- Cytomegalovirus (CMV)
2 Primary · 12 Secondary · Reporting Duration: Baseline through study completion, an average of 1 year
Awards & Highlights
1 Treatment Group
Viral Specific T-Lymphocytes
1 of 1
25 Total Participants · 1 Treatment Group
Primary Treatment: Epstein-Barr Virus Specific T-Lymphocytes · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 1 - 60 · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is the participation of octogenarians permissible in this research?
"The requirements for this trial involve patients aged 1 Month to 60. In comparison, there are 216 trials designed with minors in mind and 651 studies catering to seniors." - Anonymous Online Contributor
Are there currently any open opportunities to participate in this experiment?
"Affirmative. According to information found on clinicaltrials.gov, this trial is actively seeking out participants and was posted in August 12th 2020 with its last update being made two years later. A total of 25 patients are required for the study at 1 location." - Anonymous Online Contributor
What is the current enrollment count for this trial?
"Affirmative. Clinicaltrials.gov's records suggest that this medical trial, which was launched on December 8th 2020 is presently recruiting participants. 25 individuals need to be recruited from a single healthcare facility." - Anonymous Online Contributor
What aims are being sought after with this research endeavor?
"The objective of this research, calculated over a period spanning Day 0 to 30 days post-cellular infusion, is to measure the severity of Grade III-IV Acute Graft versus Host Disease. Secondary metrics include Viral Load as determined by Polymerase Chain Reaction (PCR), 6-month Survival Rates and Viral Load from Stool Samples." - Anonymous Online Contributor
Am I a candidate for this investigation?
"This medical trial is recruiting 25 individuals, aged 1 month to 60 years old, with cytomegalovirus infections. In order for a patient to be eligible for enrollment they must provide informed consent (or assent if applicable), have a negative pregnancy test, demonstrate active adenovirus infection or refractory CMV viremia/adenoviremia and clinical findings consistent with EBV lymphoma. Furthermore, these participants must not be on high doses of steroids nor contraindicated from antiviral treatments prior to cellular infusion." - Anonymous Online Contributor